Since non-Hodgkin’s lymphoma is a disease of heterogeneous lymphoid malignancies, precise classification is essential for predicting the prognosis and determining the appropriate treatment strategy. Although the recent studies of gene expression profiling-based classification have successfully discriminated diffuse large B-cell lymphoma (DLBCL) into two subgroups based on the origin of lymphoma cells and their prognosis, this method is hardly applicable for the routine practice due to complexity of techniques. Because the immunohistochemistry-based classification of non-Hodgkin’s lymphoma can be easily applicable, it has been widely used in daily practice. We previously reported the favorable prognostic value of CD21 for DLBCL (
Disclosures: No relevant conflicts of interest to declare.